{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:49:01Z","timestamp":1792511341692,"version":"4.5.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,5,26]],"date-time":"2018-05-26T00:00:00Z","timestamp":1527292800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s40262-018-0679-9","type":"journal-article","created":{"date-parts":[[2018,5,26]],"date-time":"2018-05-26T00:52:06Z","timestamp":1527295926000},"page":"157-168","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":150,"title":["Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib"],"prefix":"10.1007","volume":"58","author":[{"given":"Carlyn Rose C.","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saif","family":"Abdul-Majeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Cael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan K.","family":"Barta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,26]]},"reference":[{"issue":"2","key":"679_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nrd1959","volume":"5","author":"I S\u00e1nchez-Serrano","year":"2006","unstructured":"S\u00e1nchez-Serrano I. Success in translational research: lessons from the development of bortezomib. Nat Rev Drug Discov. 2006;5(2):107\u201314. https:\/\/doi.org\/10.1038\/nrd1959 .","journal-title":"Nat Rev Drug Discov."},{"issue":"11","key":"679_CR2","first-page":"2615","volume":"59","author":"J Adams","year":"1999","unstructured":"Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59(11):2615\u201322.","journal-title":"Cancer Res."},{"issue":"3\u20134","key":"679_CR3","first-page":"131","volume":"378","author":"AL Goldberg","year":"1997","unstructured":"Goldberg AL, Akopian TN, Kisselev AF, Lee DH, Rohrwild M. New insights into the mechanisms and importance of the proteasome in intracellular protein degradation. Biol Chem. 1997;378(3\u20134):131\u201340.","journal-title":"Biol Chem."},{"issue":"6","key":"679_CR4","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1073\/pnas.95.6.2727","volume":"95","author":"A Ciechanover","year":"1998","unstructured":"Ciechanover A, Schwartz AL. The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. Proc Natl Acad Sci USA. 1998;95(6):2727\u201330.","journal-title":"Proc Natl Acad Sci USA."},{"key":"679_CR5","doi-asserted-by":"publisher","unstructured":"Ciechanover A, Orian A, Schwartz AL. Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays. 2000;22(5):442\u201351. https:\/\/doi.org\/10.1002\/(sici)1521-1878(200005)22:5<442::aid-bies6>3.0.co;2-q .","DOI":"10.1002\/(sici)1521-1878(200005)22:5<442::aid-bies6>3.0.co;2-q"},{"issue":"5","key":"679_CR6","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0092-8674(94)90482-0","volume":"78","author":"VJ Palombella","year":"1994","unstructured":"Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell. 1994;78(5):773\u201385.","journal-title":"Cell."},{"issue":"5288","key":"679_CR7","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1126\/science.274.5288.782","volume":"274","author":"AA Beg","year":"1996","unstructured":"Beg AA, Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science. 1996;274(5288):782\u20134.","journal-title":"Science."},{"issue":"5288","key":"679_CR8","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1126\/science.274.5288.787","volume":"274","author":"DJ Antwerp Van","year":"1996","unstructured":"Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science. 1996;274(5288):787\u20139.","journal-title":"Science."},{"issue":"5288","key":"679_CR9","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1126\/science.274.5288.784","volume":"274","author":"CY Wang","year":"1996","unstructured":"Wang CY, Mayo MW, Baldwin AS. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science. 1996;274(5288):784\u20137.","journal-title":"Science."},{"issue":"4","key":"679_CR10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0960-894X(98)00029-8","volume":"8","author":"J Adams","year":"1998","unstructured":"Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett. 1998;8(4):333\u20138.","journal-title":"Bioorg Med Chem Lett."},{"issue":"5","key":"679_CR11","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1535-6108(04)00120-5","volume":"5","author":"J Adams","year":"2004","unstructured":"Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell. 2004;5(5):417\u201321.","journal-title":"Cancer Cell."},{"issue":"6","key":"679_CR12","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/S0955-0674(97)80079-8","volume":"9","author":"A Hershko","year":"1997","unstructured":"Hershko A. Roles of ubiquitin-mediated proteolysis in cell cycle control. Curr Opin Cell Biol. 1997;9(6):788\u201399.","journal-title":"Curr Opin Cell Biol."},{"issue":"1","key":"679_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1006\/bbrc.1998.8604","volume":"246","author":"T Oikawa","year":"1998","unstructured":"Oikawa T, Sasaki T, Nakamura M, Shimamura M, Tanahashi N, Omura S, et al. The proteasome is involved in angiogenesis. Biochem Biophys Res Commun. 1998;246(1):243\u20138. https:\/\/doi.org\/10.1006\/bbrc.1998.8604 .","journal-title":"Biochem Biophys Res Commun."},{"issue":"4","key":"679_CR14","first-page":"219","volume":"4","author":"BR Zetter","year":"1993","unstructured":"Zetter BR. Adhesion molecules in tumor metastasis. Semin Cancer Biol. 1993;4(4):219\u201329.","journal-title":"Semin Cancer Biol."},{"issue":"5","key":"679_CR15","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/1074-7613(95)90030-6","volume":"2","author":"MA Read","year":"1995","unstructured":"Read MA, Neish AS, Luscinskas FW, Palombella VJ, Maniatis T, Collins T. The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity. 1995;2(5):493\u2013506.","journal-title":"Immunity."},{"issue":"7","key":"679_CR16","first-page":"3071","volume":"61","author":"T Hideshima","year":"2001","unstructured":"Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61(7):3071\u20136.","journal-title":"Cancer Res."},{"issue":"4","key":"679_CR17","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1182\/blood-2002-08-2543","volume":"101","author":"T Hideshima","year":"2003","unstructured":"Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003;101(4):1530\u20134. https:\/\/doi.org\/10.1182\/blood-2002-08-2543 .","journal-title":"Blood."},{"issue":"24","key":"679_CR18","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487\u201398. https:\/\/doi.org\/10.1056\/NEJMoa043445 .","journal-title":"N Engl J Med."},{"issue":"9","key":"679_CR19","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906\u201317. https:\/\/doi.org\/10.1056\/NEJMoa0801479 .","journal-title":"N Engl J Med."},{"issue":"8","key":"679_CR20","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","volume":"120","author":"L Rosi\u00f1ol","year":"2012","unstructured":"Rosi\u00f1ol L, Oriol A, Teruel AI, Hern\u00e1ndez D, L\u00f3pez-Jim\u00e9nez J, de la Rubia J, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study. Blood. 2012;120(8):1589\u201396. https:\/\/doi.org\/10.1182\/blood-2012-02-408922 .","journal-title":"Blood."},{"issue":"8","key":"679_CR21","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754\u201366. https:\/\/doi.org\/10.1056\/NEJMoa1606038 .","journal-title":"N Engl J Med."},{"issue":"10068","key":"679_CR22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BG Durie","year":"2017","unstructured":"Durie BG, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519\u201327. https:\/\/doi.org\/10.1016\/S0140-6736(16)31594-X .","journal-title":"Lancet."},{"issue":"10","key":"679_CR23","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","volume":"110","author":"PG Richardson","year":"2007","unstructured":"Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110(10):3557\u201360. https:\/\/doi.org\/10.1182\/blood-2006-08-036947 .","journal-title":"Blood."},{"issue":"16","key":"679_CR24","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1517\/14656566.2014.965142","volume":"15","author":"P Bose","year":"2014","unstructured":"Bose P, Batalo MS, Holkova B, Grant S. Bortezomib for the treatment of non-Hodgkin\u2019s lymphoma. Expert Opin Pharmacother. 2014;15(16):2443\u201359. https:\/\/doi.org\/10.1517\/14656566.2014.965142 .","journal-title":"Expert Opin Pharmacother."},{"issue":"5","key":"679_CR25","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","volume":"120","author":"P Moreau","year":"2012","unstructured":"Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, et al. Proteasome inhibitors in multiple myeloma: 10\u00a0years later. Blood. 2012;120(5):947\u201359. https:\/\/doi.org\/10.1182\/blood-2012-04-403733 .","journal-title":"Blood."},{"key":"679_CR26","doi-asserted-by":"publisher","first-page":"CD010816","DOI":"10.1002\/14651858.cd010816.pub2","volume":"4","author":"K Scott","year":"2016","unstructured":"Scott K, Hayden PJ, Will A, Wheatley K, Coyne I. Bortezomib for the treatment of multiple myeloma. Cochrane Database Syst Rev. 2016;4:CD010816. https:\/\/doi.org\/10.1002\/14651858.cd010816.pub2 .","journal-title":"Cochrane Database Syst Rev."},{"issue":"5","key":"679_CR27","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","volume":"12","author":"P Moreau","year":"2011","unstructured":"Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431\u201340. https:\/\/doi.org\/10.1016\/S1470-2045(11)70081-X .","journal-title":"Lancet Oncol."},{"issue":"9","key":"679_CR28","first-page":"2638","volume":"5","author":"BA Teicher","year":"1999","unstructured":"Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res. 1999;5(9):2638\u201345.","journal-title":"Clin Cancer Res."},{"issue":"6","key":"679_CR29","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s00280-011-1637-5","volume":"68","author":"TB Leal","year":"2011","unstructured":"Leal TB, Remick SC, Takimoto CH, Ramanathan RK, Davies A, Egorin MJ, et al. Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. Cancer Chemother Pharmacol. 2011;68(6):1439\u201347. https:\/\/doi.org\/10.1007\/s00280-011-1637-5 .","journal-title":"Cancer Chemother Pharmacol."},{"issue":"10","key":"679_CR30","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1158\/1078-0432.CCR-11-2873","volume":"18","author":"PM LoRusso","year":"2012","unstructured":"LoRusso PM, Venkatakrishnan K, Ramanathan RK, Sarantopoulos J, Mulkerin D, Shibata SI, et al. Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432. Clin Cancer Res. 2012;18(10):2954\u201363. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-2873 .","journal-title":"Clin Cancer Res."},{"issue":"11","key":"679_CR31","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1200\/JCO.2004.02.106","volume":"22","author":"CN Papandreou","year":"2004","unstructured":"Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 2004;22(11):2108\u201321. https:\/\/doi.org\/10.1200\/JCO.2004.02.106 .","journal-title":"J Clin Oncol."},{"issue":"12","key":"679_CR32","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.3324\/haematol.13285","volume":"93","author":"P Moreau","year":"2008","unstructured":"Moreau P, Coiteux V, Hulin C, Leleu X, van de Velde H, Acharya M, et al. Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica. 2008;93(12):1908\u201311. https:\/\/doi.org\/10.3324\/haematol.13285 .","journal-title":"Haematologica."},{"issue":"14 Suppl. 11","key":"679_CR33","first-page":"14","volume":"18","author":"R Schwartz","year":"2004","unstructured":"Schwartz R, Davidson T. Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology (Williston Park). 2004;18(14 Suppl. 11):14\u201321.","journal-title":"Oncology (Williston Park)."},{"issue":"1","key":"679_CR34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00280-010-1283-3","volume":"67","author":"DE Reece","year":"2011","unstructured":"Reece DE, Sullivan D, Lonial S, Mohrbacher AF, Chatta G, Shustik C, et al. Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemother Pharmacol. 2011;67(1):57\u201367. https:\/\/doi.org\/10.1007\/s00280-010-1283-3 .","journal-title":"Cancer Chemother Pharmacol."},{"issue":"12","key":"679_CR35","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s40262-012-0010-0","volume":"51","author":"P Moreau","year":"2012","unstructured":"Moreau P, Karamanesht II, Domnikova N, Kyselyova MY, Vilchevska KV, Doronin VA, et al. Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. Clin Pharmacokinet. 2012;51(12):823\u20139. https:\/\/doi.org\/10.1007\/s40262-012-0010-0 .","journal-title":"Clin Pharmacokinet."},{"issue":"4","key":"679_CR36","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1021\/tx050313d","volume":"19","author":"J Labutti","year":"2006","unstructured":"Labutti J, Parsons I, Huang R, Miwa G, Gan LS, Daniels JS. Oxidative deboronation of the peptide boronic acid proteasome inhibitor bortezomib: contributions from reactive oxygen species in this novel cytochrome P450 reaction. Chem Res Toxicol. 2006;19(4):539\u201346. https:\/\/doi.org\/10.1021\/tx050313d .","journal-title":"Chem Res Toxicol."},{"issue":"6","key":"679_CR37","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1124\/dmd.104.002956","volume":"33","author":"T Pekol","year":"2005","unstructured":"Pekol T, Daniels JS, Labutti J, Parsons I, Nix D, Baronas E, et al. Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab Dispos. 2005;33(6):771\u20137. https:\/\/doi.org\/10.1124\/dmd.104.002956 .","journal-title":"Drug Metab Dispos."},{"issue":"11","key":"679_CR38","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1124\/dmd.105.005710","volume":"33","author":"V Uttamsingh","year":"2005","unstructured":"Uttamsingh V, Lu C, Miwa G, Gan LS. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Dispos. 2005;33(11):1723\u20138. https:\/\/doi.org\/10.1124\/dmd.105.005710 .","journal-title":"Drug Metab Dispos."},{"issue":"11","key":"679_CR39","doi-asserted-by":"publisher","first-page":"504","DOI":"10.5414\/CPP38504","volume":"38","author":"GI K\u00f6hler","year":"2000","unstructured":"K\u00f6hler GI, Bode-B\u00f6ger SM, Busse R, Hoopmann M, Welte T, B\u00f6ger RH. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther. 2000;38(11):504\u201313.","journal-title":"Int J Clin Pharmacol Ther."},{"issue":"10","key":"679_CR40","doi-asserted-by":"publisher","first-page":"769","DOI":"10.2165\/00002512-200320100-00005","volume":"20","author":"T Egger","year":"2003","unstructured":"Egger T, Dormann H, Ahne G, Runge U, Neubert A, Criegee-Rieck M, et al. Identification of adverse drug reactions in geriatric inpatients using a computerised drug database. Drugs Aging. 2003;20(10):769\u201376.","journal-title":"Drugs Aging."},{"issue":"2","key":"679_CR41","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1365-2710.2007.00815.x","volume":"32","author":"KC Sokol","year":"2007","unstructured":"Sokol KC, Knudsen JF, Li MM. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Ther. 2007;32(2):169\u201375. https:\/\/doi.org\/10.1111\/j.1365-2710.2007.00815.x .","journal-title":"J Clin Pharm Ther."},{"issue":"4","key":"679_CR42","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1046\/j.1365-2796.2001.00892.x","volume":"250","author":"I Buajordet","year":"2001","unstructured":"Buajordet I, Ebbesen J, Erikssen J, Br\u00f8rs O, Hilberg T. Fatal adverse drug events: the paradox of drug treatment. J Intern Med. 2001;250(4):327\u201341.","journal-title":"J Intern Med."},{"issue":"5","key":"679_CR43","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/bjc.2013.48","volume":"108","author":"RW Leeuwen van","year":"2013","unstructured":"van Leeuwen RW, Brundel DH, Neef C, van Gelder T, Mathijssen RH, Burger DM, et al. Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer. 2013;108(5):1071\u20138. https:\/\/doi.org\/10.1038\/bjc.2013.48 .","journal-title":"Br J Cancer."},{"issue":"8","key":"679_CR44","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1093\/jnci\/djk130","volume":"99","author":"RP Riechelmann","year":"2007","unstructured":"Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007;99(8):592\u2013600. https:\/\/doi.org\/10.1093\/jnci\/djk130 .","journal-title":"J Natl Cancer Inst."},{"issue":"10","key":"679_CR45","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1093\/annonc\/mdq761","volume":"22","author":"RW Leeuwen van","year":"2011","unstructured":"van Leeuwen RW, Swart EL, Boven E, Boom FA, Schuitenmaker MG, Hugtenburg JG. Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol. 2011;22(10):2334\u201341. https:\/\/doi.org\/10.1093\/annonc\/mdq761 .","journal-title":"Ann Oncol."},{"issue":"1","key":"679_CR46","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103\u201341. https:\/\/doi.org\/10.1016\/j.pharmthera.2012.12.007 .","journal-title":"Pharmacol Ther."},{"issue":"Pt 2","key":"679_CR47","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1016\/j.clinthera.2009.11.012","volume":"31","author":"K Venkatakrishnan","year":"2009","unstructured":"Venkatakrishnan K, Rader M, Ramanathan RK, Ramalingam S, Chen E, Riordan W, et al. Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug\u2013drug interaction study. Clin Ther. 2009;31(Pt 2):2444\u201358. https:\/\/doi.org\/10.1016\/j.clinthera.2009.11.012 .","journal-title":"Clin Ther."},{"issue":"3","key":"679_CR48","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2165\/00003088-200948030-00006","volume":"48","author":"DI Quinn","year":"2009","unstructured":"Quinn DI, Nemunaitis J, Fuloria J, Britten CD, Gabrail N, Yee L, et al. Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin\u2019s lymphoma or multiple myeloma. Clin Pharmacokinet. 2009;48(3):199\u2013209. https:\/\/doi.org\/10.2165\/00003088-200948030-00006 .","journal-title":"Clin Pharmacokinet."},{"issue":"12","key":"679_CR49","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2165\/11594410-000000000-00000","volume":"50","author":"A Hellmann","year":"2011","unstructured":"Hellmann A, Rule S, Walewski J, Shpilberg O, Feng H, van de Velde H, et al. Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin\u2019s lymphoma. Clin Pharmacokinet. 2011;50(12):781\u201391. https:\/\/doi.org\/10.2165\/11594410-000000000-00000 .","journal-title":"Clin Pharmacokinet."},{"issue":"6","key":"679_CR50","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.3109\/10428194.2015.1096354","volume":"57","author":"A Grelaud","year":"2016","unstructured":"Grelaud A, Fourrier-R\u00e9glat A, Fitoussi O, Facon T, Jov\u00e9 J, B\u00e9nichou J, et al. Patterns and effectiveness of bortezomib use according to age in the VESUVE cohort. Leuk Lymphoma. 2016;57(6):1349\u201354. https:\/\/doi.org\/10.3109\/10428194.2015.1096354 .","journal-title":"Leuk Lymphoma."},{"issue":"8","key":"679_CR51","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/ajh.24094","volume":"90","author":"JM Vose","year":"2015","unstructured":"Vose JM. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2015;90(8):739\u201345. https:\/\/doi.org\/10.1002\/ajh.24094 .","journal-title":"Am J Hematol."},{"issue":"1","key":"679_CR52","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","volume":"57","author":"AA Mangoni","year":"2004","unstructured":"Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6\u201314.","journal-title":"Br J Clin Pharmacol."},{"issue":"2","key":"679_CR53","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/03602530902722679","volume":"41","author":"U Klotz","year":"2009","unstructured":"Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67\u201376. https:\/\/doi.org\/10.1080\/03602530902722679 .","journal-title":"Drug Metab Rev."},{"issue":"17","key":"679_CR54","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","volume":"118","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Blad\u00e9 J, Mateos MV, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood. 2011;118(17):4519\u201329. https:\/\/doi.org\/10.1182\/blood-2011-06-358812 .","journal-title":"Blood."},{"issue":"9","key":"679_CR55","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/jcph.906","volume":"57","author":"MJ Hanley","year":"2017","unstructured":"Hanley MJ, Mould DR, Taylor TJ, Gupta N, Suryanarayan K, Neuwirth R, et al. Population pharmacokinetic analysis of bortezomib in pediatric leukemia patients: model-based support for body surface area-based dosing over the 2- to 16-year age range. J Clin Pharmacol. 2017;57(9):1183\u201393. https:\/\/doi.org\/10.1002\/jcph.906 .","journal-title":"J Clin Pharmacol."},{"issue":"5","key":"679_CR56","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2165\/11599410-000000000-00000","volume":"51","author":"MJ Brill","year":"2012","unstructured":"Brill MJ, Diepstraten J, van Rongen A, van Kralingen S, van den Anker JN, Knibbe CA. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 2012;51(5):277\u2013304. https:\/\/doi.org\/10.2165\/11599410-000000000-00000 .","journal-title":"Clin Pharmacokinet."},{"issue":"5","key":"679_CR57","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/46.5.673","volume":"46","author":"ES Lightcap","year":"2000","unstructured":"Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Proteasome inhibition measurements: clinical application. Clin Chem. 2000;46(5):673\u201383.","journal-title":"Clin Chem."},{"issue":"8","key":"679_CR58","first-page":"2505","volume":"8","author":"C Aghajanian","year":"2002","unstructured":"Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res. 2002;8(8):2505\u201311.","journal-title":"Clin Cancer Res."},{"issue":"22","key":"679_CR59","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","volume":"20","author":"RZ Orlowski","year":"2002","unstructured":"Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002;20(22):4420\u20137. https:\/\/doi.org\/10.1200\/JCO.2002.01.133 .","journal-title":"J Clin Oncol."},{"issue":"2","key":"679_CR60","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","volume":"127","author":"S Jagannath","year":"2004","unstructured":"Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127(2):165\u201372. https:\/\/doi.org\/10.1111\/j.1365-2141.2004.05188.x .","journal-title":"Br J Haematol."},{"issue":"26","key":"679_CR61","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609\u201317. https:\/\/doi.org\/10.1056\/NEJMoa030288 .","journal-title":"N Engl J Med."},{"issue":"13","key":"679_CR62","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","volume":"28","author":"MV Mateos","year":"2010","unstructured":"Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010;28(13):2259\u201366. https:\/\/doi.org\/10.1200\/JCO.2009.26.0638 .","journal-title":"J Clin Oncol."},{"issue":"7","key":"679_CR63","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1182\/bloodadvances.2016003905","volume":"1","author":"C Botta","year":"2017","unstructured":"Botta C, Ciliberto D, Rossi M, Staropoli N, Cuc\u00e8 M, Galeano T, et al. Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed\/refractory patients. Blood Adv. 2017;1(7):455\u201366. https:\/\/doi.org\/10.1182\/bloodadvances.2016003905 .","journal-title":"Blood Adv."},{"issue":"37","key":"679_CR64","doi-asserted-by":"publisher","first-page":"62435","DOI":"10.18632\/oncotarget.18722","volume":"8","author":"J Liu","year":"2017","unstructured":"Liu J, Yang H, Liang X, Wang Y, Hou J, Liu Y, et al. Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed\/refractory multiple myeloma with del(17p). Oncotarget. 2017;8(37):62435\u201344. https:\/\/doi.org\/10.18632\/oncotarget.18722 .","journal-title":"Oncotarget."},{"issue":"23","key":"679_CR65","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1002\/cncr.28325","volume":"119","author":"AK Nooka","year":"2013","unstructured":"Nooka AK, Kaufman JL, Behera M, Langston A, Waller EK, Flowers CR, et al. Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials. Cancer. 2013;119(23):4119\u201328. https:\/\/doi.org\/10.1002\/cncr.28325 .","journal-title":"Cancer."},{"issue":"7","key":"679_CR66","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00277-013-1711-7","volume":"92","author":"Z Zeng","year":"2013","unstructured":"Zeng Z, Lin J, Chen J. Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Ann Hematol. 2013;92(7):935\u201343. https:\/\/doi.org\/10.1007\/s00277-013-1711-7 .","journal-title":"Ann Hematol."},{"issue":"24","key":"679_CR67","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","volume":"30","author":"P Sonneveld","year":"2012","unstructured":"Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial. J Clin Oncol. 2012;30(24):2946\u201355. https:\/\/doi.org\/10.1200\/JCO.2011.39.6820 .","journal-title":"J Clin Oncol."},{"issue":"33","key":"679_CR68","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1200\/JCO.2014.58.7618","volume":"33","author":"R Niesvizky","year":"2015","unstructured":"Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B, et al. Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens. J Clin Oncol. 2015;33(33):3921\u20139. https:\/\/doi.org\/10.1200\/JCO.2014.58.7618 .","journal-title":"J Clin Oncol."},{"issue":"10","key":"679_CR69","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa1412096","volume":"372","author":"T Robak","year":"2015","unstructured":"Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372(10):944\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1412096 .","journal-title":"N Engl J Med."},{"issue":"30","key":"679_CR70","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","unstructured":"Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24(30):4867\u201374. https:\/\/doi.org\/10.1200\/JCO.2006.07.9665 .","journal-title":"J Clin Oncol."},{"issue":"3","key":"679_CR71","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/annonc\/mdn656","volume":"20","author":"A Goy","year":"2009","unstructured":"Goy A, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2009;20(3):520\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdn656 .","journal-title":"Ann Oncol."},{"issue":"6","key":"679_CR72","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","volume":"28","author":"E Kastritis","year":"2010","unstructured":"Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010;28(6):1031\u20137. https:\/\/doi.org\/10.1200\/JCO.2009.23.8220 .","journal-title":"J Clin Oncol."},{"issue":"2","key":"679_CR73","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3324\/haematol.11627","volume":"93","author":"AD Wechalekar","year":"2008","unstructured":"Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Efficacy of bortezomib in systemic AL amyloidosis with relapsed\/refractory clonal disease. Haematologica. 2008;93(2):295\u20138. https:\/\/doi.org\/10.3324\/haematol.11627 .","journal-title":"Haematologica."},{"issue":"2","key":"679_CR74","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00277-010-1062-6","volume":"90","author":"W Lamm","year":"2011","unstructured":"Lamm W, Willenbacher W, Lang A, Zojer N, M\u00fcld\u00fcr E, Ludwig H, et al. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Ann Hematol. 2011;90(2):201\u20136. https:\/\/doi.org\/10.1007\/s00277-010-1062-6 .","journal-title":"Ann Hematol."},{"issue":"19","key":"679_CR75","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","volume":"119","author":"JR Mikhael","year":"2012","unstructured":"Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119(19):4391\u20134. https:\/\/doi.org\/10.1182\/blood-2011-11-390930 .","journal-title":"Blood."},{"issue":"19","key":"679_CR76","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","volume":"119","author":"CP Venner","year":"2012","unstructured":"Venner CP, Lane T, Foard D, Rannigan L, Gibbs SD, Pinney JH, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 2012;119(19):4387\u201390. https:\/\/doi.org\/10.1182\/blood-2011-10-388462 .","journal-title":"Blood."},{"issue":"8","key":"679_CR77","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1182\/blood-2009-02-203398","volume":"114","author":"DE Reece","year":"2009","unstructured":"Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood. 2009;114(8):1489\u201397. https:\/\/doi.org\/10.1182\/blood-2009-02-203398 .","journal-title":"Blood."},{"issue":"23","key":"679_CR78","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1200\/JCO.2008.20.4677","volume":"27","author":"SP Treon","year":"2009","unstructured":"Treon SP, Ioakimidis L, Soumerai JD, Patterson CJ, Sheehy P, Nelson M, et al. Primary therapy of Waldenstr\u00f6m macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009;27(23):3830\u20135. https:\/\/doi.org\/10.1200\/JCO.2008.20.4677 .","journal-title":"J Clin Oncol."},{"issue":"12","key":"679_CR79","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1200\/JCO.2006.07.8659","volume":"25","author":"CI Chen","year":"2007","unstructured":"Chen CI, Kouroukis CT, White D, Voralia M, Stadtmauer E, Stewart AK, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom\u2019s macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(12):1570\u20135. https:\/\/doi.org\/10.1200\/JCO.2006.07.8659 .","journal-title":"J Clin Oncol."},{"issue":"9","key":"679_CR80","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/ajh.21788","volume":"85","author":"IM Ghobrial","year":"2010","unstructured":"Ghobrial IM, Xie W, Padmanabhan S, Badros A, Rourke M, Leduc R, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstr\u00f6m macroglobulinemia. Am J Hematol. 2010;85(9):670\u20134. https:\/\/doi.org\/10.1002\/ajh.21788 .","journal-title":"Am J Hematol."},{"issue":"19","key":"679_CR81","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1182\/blood-2013-05-503862","volume":"122","author":"MA Dimopoulos","year":"2013","unstructured":"Dimopoulos MA, Garc\u00eda-Sanz R, Gavriatopoulou M, Morel P, Kyrtsonis MC, Michalis E, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood. 2013;122(19):3276\u201382. https:\/\/doi.org\/10.1182\/blood-2013-05-503862 .","journal-title":"Blood."},{"issue":"19","key":"679_CR82","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","volume":"24","author":"PG Richardson","year":"2006","unstructured":"Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24(19):3113\u201320. https:\/\/doi.org\/10.1200\/JCO.2005.04.7779 .","journal-title":"J Clin Oncol."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-018-0679-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-018-0679-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-018-0679-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T14:38:10Z","timestamp":1604327890000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-018-0679-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,26]]},"references-count":82,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["679"],"URL":"https:\/\/doi.org\/10.1007\/s40262-018-0679-9","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,26]]},"assertion":[{"value":"26 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used to assist in the preparation of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"CRT, SAM, and BC have no conflicts of interest directly relevant to the content of this review. SKB has received research support from Merck, Celgene, Seattle Genetics, Takeda, and Bayer and has received fees for participation in an independent Data and Safety Monitoring Board (DSMB) for Janssen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}